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A B S T R A C TDisease etiology may be regarded as a consequence of both genotypic
and biochemical phenomena, which impact individual patients in
different ways. Disease prognosis, beneﬁcial treatment response, and
susceptibility to adverse drug effects are often intimately tied to
individual biology. Clinical and genetic biomarkers applied individu-
ally or in concert are increasingly used to stratify patient populations
in terms of prognosis, therapeutic beneﬁt, or safety. As a result,
clinical trialists are challenged to design studies that reﬂect these
determinants of outcome, to optimize the patient’s eventual clinical
course both in the trial and in actual practice. These designs are
informed both by preclinical studies and by real-world research that
can establish proof of concept for a novel biomarker and provide a
basic understanding of the relationship between biomarker and
clinical outcome. As clinical and real-world studies unfold, a deeper
understanding of the nature of the biomarker and its potential uses insee front matter Copyright & 2013, International S
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ndence to: Leah Burns, Bristol-Myers Squibb, Routdrug development is gained. Speciﬁcally, one can eventually deﬁne the
biomarker as prognostic (i.e., predicts disease progression), predictive
(predicts treatment response or adverse outcome(s)), or exhibiting both
prognostic and predictive properties. One must further validate the
performance of these emerging biomarkers, again in both the trial and
real-world environments. The eventual adoption of the biomarker as a
useful pharmacodiagnostic test is premised upon this early translational
research. In this article, the development and validation of predictive
and prognostic biomarkers is discussed by using selected examples that
highlight factors contributing to the valuation of biomarkers and their
application to personalized medicine in the real world.
Keywords: biomarkers, drug industry, economics, personalized
medicine, pharmacodiagnostics.
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The core belief that underscores the concept of personalized
medicine (PM) (i.e., the right therapy in the right patient at the
right time) is that PM will both expedite drug development and
lead to greater efﬁciencies in health care. Furthermore, as
economic pressures emerge to constrain the health care system,
the dual promise that PM might favorably address these chal-
lenges becomes even more important.
The processes inherent to the conduct of PM research are
complex, and require considerable investigation. Experience has
shown, for example, that genetic markers are neither perfect pre-
dictors of prognosis (e.g. APOe4 in Alzheimer’s disease [AD]) nor
response (e.g., CYP2 with clopidogrel) [1,2]. Furthermore, biomarker
qualiﬁcation requires the concerted effort of the diagnostic developer,
regulatory bodies, and the therapeutic sponsor. These parties inher-
ently have different priorities. For example, the diagnostic test
developer may simply wish to produce a saleable product (i.e., a test
kit), and may do so in the absence of regulatory endorsement. The
regulator, while concerned about reliability and reproducibility, may
offer no clear guidance as to the acceptable coefﬁcient of variability of
the diagnostic assay, nor its prognostic accuracy, other than setting agoal of “trial enrichment” [3,4]. The drug developer while looking for
ways to optimize beneﬁt/risk may be reluctant to wed its therapy to a
particular diagnostic, given that the life cycle of the former is likely to
be much greater than that of the latter. Appropriate end-point
deﬁnition has proven to be an even greater challenge.
In spite of all these challenges, the feasibility of a PM paradigm
has been demonstrated for a variety of therapies in a number of
disease states. Genomic research, coupled with advancements in
large-scale database informatics technology, does permit the
development and validation of biomarker algorithms that can
reliably predict disease progression and/or treatment response.
Biomarkers can also be developed for products that have long been
marketed to optimize the risk/beneﬁt proﬁle of the therapeutic.
In this article, three examples of prognostic and/or predictive
biomarker validation either derived in concert with drug develop-
ment or long after market authorization are highlighted. These
examples are drawn from three disease areas: neuroscience (AD),
virology (hepatitis C), and cardiovascular disease (stroke preven-
tion). How these research endeavors support a PM strategy that
highlights the value of both the diagnostic and the therapy, thus
contributing to the PM vision of optimal patient care at an
optimal cost, is also described.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Perhaps no area of clinical research has beneﬁted more from the
development of prognostic algorithms than AD. Despite recent
discouraging results from several clinical trials in both mild/
moderate and predementia AD [5–7], the ability to diagnose the
disease in its early stages and reliably predict progression has
been greatly enhanced by such research. Deﬁning the window of
opportunity for early intervention can catalyze lifestyle changes
or intervention with investigational disease-modifying therapies
(DMTs) in the hopes of changing the course of this devastating
disease, bringing the science closer to true patient beneﬁt [8].
Improved diagnostic testing is a consequence of concerted
research in a variety of areas that include discovery (assay
development and validation), external database research (e.g.,
AD Neuroimaging Initiative), and the clinical trial experience
with several candidate therapies. For example, assays that
quantify the levels of certain proteins that are regarded as
precursors to amyloid deposition in the brain have been incorpo-
rated into observational longitudinal databases [9]. These data
are then used to reﬁne the assays themselves and to develop
algorithms incorporating assay test results and other clinical
information to deﬁne patients according to progression risk [10].
Several studies have shown that certain cerebrospinal ﬂuid
markers, associated with the pathology of and eventual develop-
ment of AD dementia, can be used to help assess the risk of
progression among patients accompanied by early changes in
cognition. Of these, the established cerebrospinal ﬂuid bio-
markers of AD (amyloid beta [Aβ40-42, tau, and tau phosphorylated
at threonine 181 [p-tau]) [11–13] have demonstrated good sensi-
tivity and speciﬁcity for predicting the progression to AD demen-
tia in patients with mild cognitive impairment [14–16]. Total-Tau
protein has also demonstrates properties of a prognostic bio-
marker. The current state of the sciences permits the prediction
that patients who present with mild cognitive impairment and
who exhibit abnormal amyloid pathology based on validated cut
points for the cerebrospinal ﬂuid markers are approximately 40%
more likely to progress to AD within 2 or 3 years. Additional
markers of Alzheimer’s pathology, for example, positron emis-
sion tomography scans and volumetric magnetic resonance
imaging, have also demonstrated acceptable prognostic accuracy
in both clinical trials and observational longitudinal studies [17].
A recent important study by Derby et al. [18] demonstrated the
superior prognostic accuracy of the Free and Cued Selective
Reminding Test over the Wechsler Memory Scale for prediction
of incident AD dementia among individuals from a community-
based cohort. The Free and Cued Selective Reminding Test is thus
better positioned to discern imminent risk for AD among patients
experiencing memory complaints, leading not only to enriched
clinical trial enrollment but also highlighting those patients who
might beneﬁt from future approved therapies.
The implications of such research are profound for two key
reasons: First, within the specialty setting, it is now feasible to
identify patients with predementia who are highly likely to
progress to AD within a few years. Patients so identiﬁed couldTable 1 – Average life-years in disease states by DMT efﬁ
DMT relative advantage DMT during predementia D
Mild Severe
10% 3.46 2.54
20% 3.78 2.40
25% 3.96 2.32
AD, Alzheimer’s disease; DMT, disease-modifying therapy; SOC, standarbe given the opportunity to enroll in well-designed clinical trials
for therapies that may delay disease progression. Second, in
clinical practice, patients with mild cognitive impairment must
be guided to make informed decisions regarding further testing
and possibly to apply nonpharmacologic lifestyle changes. Until
effective DMTs are approved, the need to conﬁrm a prognosis is
complex and indeed controversial, beyond a willingness to enroll
in a clinical trial or adapt one’s lifestyle. There are also signiﬁcant
cost implications to testing and no clear guidance as to which
entities must bear the burden of payment.
With regard to costs, pharmacoeconomics models can aid in
understanding whether or not a treatment and the accompany-
ing tests are cost-effective under different scenarios. For exam-
ple, the use of prognostic markers may prove cost-effective if
they lead to an enriched patient population in terms of risk and
when effective treatments prevent or reduce the rate of cost-
intensive events in the long term. A hypothetical model devel-
oped by Budd et al. assessed the economic implications of early
AD screening with prognostic biomarkers and use of potential
DMTs. The authors concluded that earlier treatment yielded
modest gains in total life-years; the distribution, however, was
skewed favorably toward milder disease as shown in Table 1 and
Figure 1. Speciﬁcally, if a therapy were to deliver a 25% reduction
in the annual risk of progression, treatment was projected to
increase life-years in predementia to mild AD on average from 3.2
to 4.2, while life-years spent in moderate to severe AD decreased
from 2.6 to 2.2. Accurate screening and earlier treatment with
DMTs were projected to have important patient beneﬁts in terms
of prolonging time in milder disease, reducing time spent with
more severe disease, increasing time in the community, and
reducing time in long-term care [19].Demonstrating Value of Predictive/Prognostic Biomarkers:
Hepatitis C Example
AD provides an important example of the contribution of data-
base research to prognostic biomarker development and valida-
tion. However, the establishment of these markers as predictors
of therapeutic response must await the development of effective
DMTs. A more relevant illustration of biomarker application to
both predict prognosis and treatment response is seen in hep-
atitis C. Viral genotype information, applied in concert with
additional risk factors such as high hepatitis C virus RNA load,
advanced liver ﬁbrosis stage, and African American ancestry, are
shown to be associated with poor prognosis, leading to cirrhosis
or hepatocellular carcinoma. These same viral genotype and
subtype markers are also predictive of response to standard
antiviral therapies, expressed as sustained virologic response
(SVR). Further extensive viral genotype subtyping has led to a
reﬁnement in the application of therapeutic regimens for
patients so characterized. Newer, emergent treatments for hep-
atitis C virus are anticipated to further tailor both the therapeutic
intervention and treatment duration when applied jointly with
more elaborate viral genotyping.cacies (all data in years).
MT during moderate AD SOC during moderate AD
Mild Severe Mild Severe
3.35 2.60 3.19 2.56
3.54 2.53 3.19 2.56
3.65 2.49 3.19 2.56
d of care.
Fig. 1 – Left panel: Markov model results showing the estimated count of patients (y axis) and time spent (x axis) with
moderate-severe AD when initiating DMT during predementia AD (light gray line), DMT during mild-moderate AD (medium
gray line), or SOC during mild-moderate AD (black line). Right panel: The cumulative time spent in moderate or severe AD if
initiating DMT during predementia AD (light gray line), DMT during mild-moderate AD (medium gray line), or SOC during
predementia AD (black line). AD, Alzheimer’s disease; DMT, disease-modifying therapy; SOC, standard of care.
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better tolerability and thus adherence to regimen. Further several
studies have demonstrated that early responders exhibit better
long-term outcomes to treatment [20–24]. Early response to
therapy is typically expressed as rapid virological response
(RVR) and early virological response at 12 weeks [25]. Achieving
an RVR is highly predictive of obtaining an SVR independent of
both genotype and treatment regimen [26]. Reﬁnement of geno-
typing in concert with clinical markers can lead to predictive
algorithms that can enrich RVR rates. Both treatment costs and
SVR rates can be optimized by applying these algorithms before
the selection of the therapeutic regimen. Last, patients who
achieve SVR are effectively cured of hepatitis C virus disease.
Recent modeling analyses have shown that patients who achieve
SVR early in disease experience a reduction in risk for hepatic
complications to the same level as the general population. When
application of biomarker algorithms leads to a reduction in
treatment duration, improved tolerability, and enhanced cure
rates, more favorable pharmacoeconomics outcomes are realized,
even in the context of more expensive novel therapies [27]. The
actual cost-effectiveness of each regimen, however, must be
evaluated in the context of the deﬁned population and the
deﬁned health care system.Clinical Utility of Predictive Biomarkers: Warfarin Example
Recent advances in pharmacogenomics now provide for the
development of predictive markers long after the approved
therapies have been in use. Patients can still beneﬁt from PM
enhancements derived from these predictive markers. The treat-
ment of atrial ﬁbrillation with the longstanding anticoagulant
warfarin illustrates one such example. Treatment response with
warfarin is deﬁned as maintaining the international normalized
ratio (INR), a measure of clotting tendency, within the acceptable
therapeutic range. Close adjustment, however, is typically
required to maintain optimal INR because of variable response
among individual patients. Two genetic markers, CYP2C9 and
VKORC1, were found to account for much of this variability,
eventually prompting the incorporation of genotype-guided dos-
ing strategies into warfarin’s product label [28–31]. Application of
these markers can readily improve the stability of INR with
appropriate dosing. An added beneﬁt of these dosing strategiesis seen in reducing bleeding risks with overdosing and clotting
risk associated with “underdosing.” Despite the acknowledged
beneﬁt of biomarker-guided dosing, challenges remain in their
application to clinical practice. In response to this need, at least
ﬁve clinical trials designed to validate pharmacogenetic-based
dosing are under way and a landmark database study demon-
strated a 31% reduced risk in hospitalization among genotyped
patients [32]. It remains to be seen whether these strategies can
be readily applied to established clinical practice.
Several factors have limited widespread adoption to date
including delays in the receipt of test results, efﬁcient monitoring
by traditional means (i.e., in academic centers), and lack of
availability of genetic testing in rural centers. Last, challenges
remain in terms of cost and there is a perception that testing
would need to be inexpensive or widely reimbursed to become
clinically useful. Currently, reimbursement for CYP2C9 and
VKORC1 testing is limited to new patients, and/or those who
are enrolled in select clinical trials or those patients willing to pay
out of pocket [33] for information about their risk of treatment-
related side effects [34]. The Institute of Medicine has recom-
mended a working group aimed at the assessment of clinical
utility for genomic testing for warfarin dosing and describes a
need for real-world studies evaluating various testing delivery
models and treatment settings [35]. It is becoming increasingly
clear with the approval of new (companion) diagnostics that the
evidence supporting the ability of the test result to appropriately
inﬂuence prescribing behavior is paramount for acceptance of the
test by the payer community. While the information provided by
these tests may be informative and “nice to have,” to merit an
added cost to the health care system, the test developer and/or
drug manufacturer must provide compelling evidence that the
test result is critical to delivering the right treatment to the right
patients in the right time frame.Conclusions
PM holds great promise for creating efﬁciencies in drug develop-
ment and health care delivery. Development can be streamlined
by targeting certain genetic mutations or molecular pathways,
increasing the probability of demonstrating a signiﬁcant beneﬁ-
cial treatment response among subjects enrolled in clinical
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beneﬁt and/or avoid the risk of serious adverse outcomes also
holds high potential for demonstrating value to health care
systems. We provide examples for predictive and prognostic
biomarkers highlighting the ways in which translational research
can inform development decisions and provide evidence to guide
medical decisions in the real world.
It is clear that integrating diagnostic strategies early in clinical
development can inform development choices and provide a
foundation for biomarker validation. In early development, it is
critical to understand how the therapeutic effect of the treat-
ment, characteristics of the identiﬁed patient population, and
test performance interact and affect economic value. These three
areas are intimately related such that changes in any one of the
parameters can have a large impact on a clinical development
strategy. Late adoption of PM approaches potentially limits
economic efﬁciency in drug development but may provide a
niche wherein optimal value is demonstrated.
Successful targeted medicine relies on maintaining ﬂexibility
throughout the drug development process as evidence of disease
risk and therapeutic beneﬁt builds. Optimally, clinical trial and
real-world data are evaluated early and continuously, leading to
data-driven decision making in drug development and clinically
useful PMs in the real world. The evolving ﬁeld of prognostic and
predictive diagnostic testing continues to generate complex
issues that manufacturers, providers, payers, and patients must
assimilate to realize the beneﬁts of targeted therapy. Because the
value of PM is so intimately linked by many factors both internal
and external to the development process, a much higher level of
coordination will be needed among all stakeholders to realize the
full potential of targeted development of new and innovative
therapies.
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